Download Files:
CV-6209
$160 – $1,100
Products Details
Product Description
– CV-6209 is a potent antagonist of platelet activating factor (PAF). CV-6209 inhibits the PAF-induced aggregation of rabbit and human platelets, with IC50s of 75 nM and 170 nM, respectively. CV-6209 can inhibit PAF-induced hypotension in rats[1].
Web ID
– HY-109897
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C34H60ClN3O6
References
– [1]Terashita Z, et, al. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther. 1987 Jul;242(1):263-8.|[2]Munoz-Cano R, et, al. Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study). J Investig Allergol Clin Immunol. 2017;27(3):161-168.|[3]Fernande CA, et, al. Effect of premedications in a murine model of asparaginase hypersensitivity. J Pharmacol Exp Ther. 2015 Mar;352(3):541-51.
CAS Number
– 100488-87-7
Molecular Weight
– 642.31
Compound Purity
– 98.0
SMILES
– CC[N+]1=CC=CC=C1CN(C(C)=O)C(OCC(OC)COC(NCCCCCCCCCCCCCCCCCC)=O)=O.[Cl-]
Clinical Information
– No Development Reported
Research Area
– Cardiovascular Disease
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– Platelet-activating Factor Receptor (PAFR)
Pathway
– GPCR/G Protein
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
